全文获取类型
收费全文 | 5294篇 |
免费 | 500篇 |
国内免费 | 297篇 |
专业分类
耳鼻咽喉 | 32篇 |
儿科学 | 91篇 |
妇产科学 | 116篇 |
基础医学 | 674篇 |
口腔科学 | 118篇 |
临床医学 | 659篇 |
内科学 | 885篇 |
皮肤病学 | 85篇 |
神经病学 | 310篇 |
特种医学 | 193篇 |
外科学 | 699篇 |
综合类 | 754篇 |
一般理论 | 1篇 |
预防医学 | 288篇 |
眼科学 | 125篇 |
药学 | 473篇 |
1篇 | |
中国医学 | 207篇 |
肿瘤学 | 380篇 |
出版年
2023年 | 73篇 |
2022年 | 85篇 |
2021年 | 196篇 |
2020年 | 183篇 |
2019年 | 153篇 |
2018年 | 193篇 |
2017年 | 158篇 |
2016年 | 152篇 |
2015年 | 212篇 |
2014年 | 275篇 |
2013年 | 250篇 |
2012年 | 398篇 |
2011年 | 454篇 |
2010年 | 257篇 |
2009年 | 252篇 |
2008年 | 303篇 |
2007年 | 297篇 |
2006年 | 261篇 |
2005年 | 272篇 |
2004年 | 216篇 |
2003年 | 188篇 |
2002年 | 147篇 |
2001年 | 137篇 |
2000年 | 136篇 |
1999年 | 147篇 |
1998年 | 93篇 |
1997年 | 71篇 |
1996年 | 66篇 |
1995年 | 65篇 |
1994年 | 49篇 |
1993年 | 35篇 |
1992年 | 46篇 |
1991年 | 36篇 |
1990年 | 38篇 |
1989年 | 28篇 |
1988年 | 23篇 |
1987年 | 23篇 |
1986年 | 24篇 |
1985年 | 14篇 |
1984年 | 13篇 |
1983年 | 11篇 |
1982年 | 6篇 |
1981年 | 6篇 |
1979年 | 11篇 |
1975年 | 3篇 |
1973年 | 3篇 |
1972年 | 4篇 |
1971年 | 3篇 |
1970年 | 6篇 |
1969年 | 6篇 |
排序方式: 共有6091条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
Nickel Ann-Christin Wan Xue-Yan Saban Dino-Vitali Weng Yin-Lun Zhang Shu Keyvani Kathy Sure Ulrich Zhu Yuan 《Journal of neuro-oncology》2019,141(1):31-41
Journal of Neuro-Oncology - Glioblastoma (GBM) is one of the most aggressive and incurable primary brain tumors. Identification of novel therapeutic targets is an urgent priority. Programmed cell... 相似文献
5.
目的 解析真实世界中乳腺恶性肿瘤患者的人群特征、诊断特征、中西医用药特征,为乳腺癌的临床防治提供参考。方法 采集2002年2月至2015年5月全国60家三级甲等医 院信息系统(Hospital Information System,HIS)中,出院诊断为“乳腺癌”的患者用药信息,采用SAS9.3统计软件,对人口学信息、诊断信息、医嘱用药信息等进行描述性分析。结果 39798例乳腺癌患者,平均年龄(50.93者,平均年龄)岁;多以门诊入院,入院病情以“一般”为主;合并疾病主要为高血压,骨肿瘤,联用西药以抑制肿瘤细胞增殖、治疗并发症、缓解放化疗不良反应为主;中医辨证以痰瘀互结证,气阴两虚证,肝气淤滞证,脾气亏虚证型最为常见,临床清热解毒剂、益气扶正剂,活血化瘀剂应用较多。结论 乳腺癌中西医结合治疗,联用药物广泛,临床治疗基本符合临床指南。 相似文献
6.
Xiuhua Weng Shaohong Luo Shen Lin Lixian Zhong Meiyue Li Rao Xin Pinfang Huang Xiongwei Xu 《Oncology research》2020,28(2):117-125
To evaluate the cost–utility of pembrolizumab versus chemotherapy as the first-line setting for metastatic nonsmall cell lung cancer (NSCLC) from the US health care system perspective, a Markov model was developed
to compare the lifetime cost and effectiveness of pembrolizumab versus chemotherapy for untreated metastatic NSCLC, based on the clinical data derived from phase III randomized controlled trial (KEYNOTE-
042; ClinicalTrials.gov; NCT02220894). Weibull distribution was fitted to simulate the parametric survival
functions. Drug costs were collected from official websites, and utility values were obtained from published literature. Total costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios
(ICERs) were computed as primary output indicators. The impact of different PD-L1 expression levels
on ICER was also evaluated. One-way and probabilistic sensitivity analyses were performed to assess the
model uncertainty. Compared with chemotherapy, patients treated with pembrolizumab provided an additional 1.13, 1.01, and 0.59 QALYs in patients with PD-L1 expression levels of ≥50%, ≥20%, and ≥1%,
with corresponding incremental cost of $53,784, $47,479, and $39,827, respectively. The resultant ICERs
of pembrolizumab versus chemotherapy were $47,596, $47,184, and $68,061/QALY, in three expression
levels of PD-L1, respectively, all of which did not exceed the WTP threshold of 180,000/QALY. Probability
sensitivity analysis outcome supported that pembrolizumab exhibited evident advantage over chemotherapy
to be cost-effective. One-way sensitivity analysis found that ICERs were most sensitive to utility value of
pembrolizumab in progression survival state. All the adjustment of parameters did not qualitatively change
the result. For treatment-naive, metastatic NSCLC patients with PD-L1+, pembrolizumab was estimated
to be cost-effective compared with chemotherapy for all PD-L1 expression levels at a WTP threshold of
$180,000/QALY in the context of the US health care system. 相似文献
7.
8.
9.
Liping Lin Megumi Suda Chenlan Xu Yuehan Zhang Yukie Yanagiba Jisheng Nie Tamie Nakajima Zuquan Weng Rui-Sheng Wang 《Journal of applied toxicology : JAT》2020,40(7):979-990
Owing to the use of ethyl tert-butyl ether (ETBE) as a fuel additive, the possible adverse effects of ETBE exposure have become a public concern. Our previous study showed that ETBE-induced toxicity in aldehyde dehydrogenase 2 (Aldh2) gene knockout (KO) mice was caused by its primary metabolite acetaldehyde, which was toxic. However, it is unclear whether tert-butyl alcohol (TBA), another main metabolite of ETBE, plays a role in ETBE-induced toxicity. To investigate this relationship, we analyzed the changes of TBA concentrations in tissues after ETBE exposure, and then evaluated the toxicity after direct TBA treatment in both KO and wild-type (WT) mice. An exposure to 500 ppm ETBE via inhalation resulted in the formation of its three metabolites, TBA, 2-methyl-1,2-propanediol and ethanol, whose concentrations in the liver, brain, fat and testis of male KO mice were significantly higher than the corresponding concentrations observed in male WT mice. Direct treatment to TBA (20 mg/mL of drinking water) caused significant changes in relative organ weights and histopathology, and increased levels of genetic damages in both types of mice. These toxic effects were also seen in KO mice exposed to a lower concentration of TBA (5 mg/mL), which was associated with increased oxidative stress in serum (reduced glutathione and reduced glutathione/oxidized glutathione ratio decreased). Our findings indicate that ALDH2 is involved in the metabolism of ETBE and TBA, and ALDH2 deficiency could greatly increase the sensitivity to TBA-induced toxicity. 相似文献
10.